FDA-approved RNA-based stool test for colorectal cancer screening.
Competing Products
Geneoscopy
Geneoscopy develops noninvasive colorectal cancer screening methods using stool sample biomarkers.
Founded
2015Geneoscopy develops noninvasive colorectal cancer screening methods using stool sample biomarkers.
Geneoscopy, founded with the mission to revolutionize gastrointestinal health, focuses on developing noninvasive colorectal cancer screening methods using biomarkers found in stool samples. The company aims to empower patients and healthcare providers by offering innovative tests that help prevent, detect, and monitor gastrointestinal diseases. Leveraging advanced molecular technologies, Geneoscopy is dedicated to improving personalized medicine and enhancing patient outcomes in the gastrointestinal health sector.
Notable figures associated with Geneoscopy include its founders and key investors who have supported the company's vision of transforming gastrointestinal diagnostics. The company has achieved significant milestones, including the development of its proprietary screening methodology and gaining recognition in the medical community for its innovative approach. Geneoscopy's impact is evident in its contribution to early disease detection and improved patient care, positioning it as a leader in the field of noninvasive diagnostic solutions for gastrointestinal health.
Companies similar to Geneoscopy include Freenome, Exact Sciences, Guardant Health and Genetron Health.
Geneoscopy was founded in 2015.
Geneoscopy's headquarters is located in St. Louis, MO, US.
Geneoscopy's most recent funding round was for $105M (USD) in January 2025.
As of Jan 1, 2025, Geneoscopy has disclosed funding of $217.9M (USD). Undisclosed round amounts are excluded.
Geneoscopy has 175 employees as of Feb 5, 2024.
Genetron Health
genetronhealth.com